Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11

Angelova, Svetlana; Jordanova, M; Spassov, Branimir; Shivarov, Velizar; Simeonova, M; Christov, Ivaylo; Angelova, Plamena R.; Alexandrova, K.; Stoimenov, Angel; Nikolova, V.; Dimova, Ivanka; Ganeva, Penka; Tzvetkov, Nikolay; Hadjiev, Evgueniy; Toshkov, Stavri

doi:10.2478/v10034-011-0043-y

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, the present study was the first to use a RNAi screening-based approach to systematically assess the effects of all human HMTs and HDTs on PCa cell viability. By using this approach, nine genes associated with PCa cell viability were identified, of which FBOX11, PRMT2, MEN1, MLL, PRDM16 and SETD4 have already been reported to be abnormally expressed in various cancer types (9)(10)(11)(12)(13)(14). The PRDM16 gene is rearranged in AML and MDS (13).…”

Section: Discussionmentioning

confidence: 99%

PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening

Zhu

Song

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Histone methylation, which is regulated by histone methyltransferases (HMTs) and histone demethylases (HDMs), has been indicated to be involved in a variety of diseases, particularly in cancer, including androgen‑independent prostate cancer (PCa). However, the functions of HMTs and HDTs in cancer have largely remained elusive. The present study, utilized an RNA interference screening using a lentiviral small hairpin (sh)RNA library to systematically elucidate the function of HMTs and HDTs in PCa cell growth and viability. Nine HMTs and HDTs, namely FBXO11, PRDM10, JMJD8, MLL, SETD4, JMJD7, PRMT2, MEN1 and PRDM16, were identified to affect DU145 cell viability, as indicated by an MTS assay subsequent to knockdown of the specific genes using shRNA pools. Furthermore, flow cytometric analysis and western blot analysis of apoptosis‑associated proteins indicated that PRDM16 has an anti‑apoptotic role in PCa cells. In addition, the spliced form, sPRDM16/MEL1S, was detected to be overexpressed in PCa cell lines. In conclusion, the present study indicated an important oncogenic role of sPRDM16/MEL1S in PCa and suggested that PRDM16 may represent a novel therapeutic target.

show abstract

Section: Discussionmentioning

confidence: 99%

PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening

Zhu

Song

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…Some authors elaborated that the expression of other gene(s) included in 8q24 amplicon is a pathogenetically important consequence [34]. This interrelationship between trisomy 8 and c-MYC amplification in myeloid leukemogenesis has been of concern, where the biological mechanism of the + 8 cell clones' onco-proliferative activity was explained by a gene dosage effect [35].…”

Section: Discussionmentioning

confidence: 99%

The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome

Attia,

Fouad,

Samy

2023

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background Chronic myeloid leukaemia is characterised by genetic instability which results in additional cytogenetic aberrations that have been linked to progression to advanced phase. Genomic study linked amplified genes in the form of c-MYC and/or the rare BCR::ABL1 genes amplification to chronic myeloid leukaemia. The effect of these genes’ amplification on patients’ characteristics and disease progression still needs further study. This cross-sectional study aimed to investigate the frequency of additional chromosomal aberrations in addition to c-MYC and BCR::ABL1 genes amplification in chronic myeloid leukaemia patients and their impact on patient’s characteristics, disease progression, and level of remission. The study included cytogenetic analysis of 49 Philadelphia positive chronic myeloid leukaemia patients and investigation of c-MYC and BCR::ABL1 genes amplification by fluorescence in situ hybridization. Results Patients with additional chromosomal aberrations represented 36.7% and had significantly lower platelet count (P = 0.003) and higher blast count (P = 0.008). The acquisition of additional chromosomal aberrations was significantly higher in chronic myeloid leukaemia patients with advanced stages (P = 0.014). Follow-up of the patients for 6 months revealed significant higher frequency of additional chromosomal aberrations in patients with failure of remission (P < 0.0001). A highly significant association between cases with failure of molecular remission (P = 0.001) and co-existing additional chromosomal aberrations. Amplification of the c-MYC gene was detected in 6 cases. The cases with c-MYC amplification showed significantly higher peripheral blood and bone marrow blasts (P = 0.029 and P = 0.008, respectively) and significantly lower platelet count (P = 0.044). Amplification of c-MYC was significantly associated with additional chromosomal aberrations (P = 0.011). Molecular remission was not achieved in any of the instances with c-MYC amplification. A highly significant association between c-MYC amplification and poor patient outcome was detected (P = 0.002). BCR::ABL1 amplification was detected in three cases, and ABL amplification was detected in four cases. Patients with BCR::ABL1 amplification showed significantly higher blast count. BCR::ABL1 amplification was significantly associated with disease progression and failure of molecular remission (P = 0.002). Conclusion Additional chromosomal aberrations, c-MYC amplification, and BCR:ABL1 amplification in chronic myeloid leukaemia stratify patients with disease progression, which may lead to better interventions and improved outcome in the future chronic myeloid leukaemia patients.

show abstract

Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies

Berry

Scott

Rowlings

et al. 2019

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11

Cited by 3 publications

References 30 publications

PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening

PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening

The study of the impact of additional chromosomal aberrations and c-MYC and BCR::ABL1 genes amplification on CML patient’s characteristics: relation to haematological parameters and patient outcome

Clinical use of SNP-microarrays for the detection of genome-wide changes in haematological malignancies

Contact Info

Product

Resources

About